Compare VIRC & MAIA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | VIRC | MAIA |
|---|---|---|
| Founded | 1950 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Industrial Specialties | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 95.5M | 77.1M |
| IPO Year | 1995 | 2022 |
| Metric | VIRC | MAIA |
|---|---|---|
| Price | $6.04 | $1.30 |
| Analyst Decision | Hold | |
| Analyst Count | 1 | 0 |
| Target Price | ★ $7.30 | N/A |
| AVG Volume (30 Days) | 30.3K | ★ 585.8K |
| Earning Date | 04-08-2026 | 05-12-2026 |
| Dividend Yield | ★ 1.65% | N/A |
| EPS Growth | N/A | ★ 33.33 |
| EPS | ★ 0.16 | N/A |
| Revenue | ★ $199,652,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $19.77 | N/A |
| P/E Ratio | $38.25 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $5.16 | $0.87 |
| 52 Week High | $9.07 | $3.19 |
| Indicator | VIRC | MAIA |
|---|---|---|
| Relative Strength Index (RSI) | 48.44 | 44.39 |
| Support Level | $6.02 | $1.20 |
| Resistance Level | $6.44 | $1.46 |
| Average True Range (ATR) | 0.15 | 0.09 |
| MACD | -0.00 | 0.01 |
| Stochastic Oscillator | 29.72 | 33.19 |
Virco Manufacturing Corp is engaged in designing, production and distributing quality furniture for the commercial and education markets. The company manufactures an assortment of products, including mobile tables, mobile storage equipment, desks, computer furniture, chairs, activity tables, folding chairs, and folding tables. Its primary furniture lines are constructed of tubular metal legs and frames, combined with wood and plastic tops, plastic seats and backs, upholstered seats and backs, and upholstered rigid polyethylene and polypropylene shells.
MAIA Biotechnology Inc is a clinical-stage biopharmaceutical company engaged in the discovery, development, and commercialization of targeted immunotherapies for cancer, with an initial focus on non-small cell lung cancer (NSCLC), which represents the majority of lung cancer cases. Its asset, ateganosine (THIO, also known as 6-thio-dG or 6-thio-deoxyguanosine), is an investigational dual mechanism of action drug candidate incorporating telomere targeting and immunogenicity. The treatment approach involves administering THIO followed by the immune checkpoint inhibitor Libtayo (cemiplimab), which is manufactured and commercialized by Regeneron.